Clinuvel Pharmaceuticals Limited Stock Nasdaq
Stocks
CUVL
US1887691038
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Nasdaq
16:00:00 2026-09-24 EDT
|
5-day change | 1st Jan Change | ||
| 5.780 USD | -0.17% |
|
-2.03% | -31.84% |
| Market Cap | 417M 292M 257M 242M 221M 413M 28.04B 2.91B 1.13B 14.27B 1.1B 1.07B 46.44B | P/E 2027 * |
11.6x | P/E 2028 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 133M 93.03M 81.83M 77.14M 70.38M 132M 8.93B 926M 359M 4.54B 349M 342M 14.79B | EV / Sales 2027 * |
1.4x | EV / Sales 2028 * | 0.96x |
| Free-Float |
83.79% | Yield 2027 * |
0.66% | Yield 2028 * | 0.79% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CUVL | Delayed | |
CBOE
| CUVL | Real-time | |
|
Deutsche Boerse AG
| UR9A | Delayed | |
|
Börse Stuttgart
| UR9A | Delayed | |
|
Boerse Muenchen
| UR9A | Real-time |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -0.17% | ||
| 1 week | -2.03% | ||
| Current month | -2.86% | ||
| 1 month | -25.90% | ||
| 3 months | -18.59% | ||
| 6 months | -15.50% | ||
| Current year | -31.84% |
| 1 week | 5.7 |  | 6.07 |
| 1 month | 5.7 | | 8.1 |
| Current year | 5.7 | | 8.67 |
| 1 year | 5.7 | | 8.92 |
| 3 years | 5.7 | | 12.06 |
| 5 years | 5.7 | | 31.15 |
| 10 years | 4.36 | | 31.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | -2.03% | - | - | 294M | |
| -0.72% | +2.76% | +40.17% | -3.49% | 80.07B | |
| +6.98% | +33.79% | +655.41% | +94.84% | 72.7B | |
| -0.07% | +2.70% | -10.41% | -28.96% | 60.45B | |
| -1.80% | -3.05% | -14.24% | +26.38% | 46.24B | |
| +0.14% | +2.81% | +3.67% | +158.04% | 45.97B | |
| -0.51% | +4.79% | +62.49% | -12.15% | 33.62B | |
| -0.16% | -0.25% | +47.20% | +114.18% | 25.26B | |
| -3.48% | +6.06% | +6.80% | +166.49% | 22.95B | |
| -0.82% | -0.77% | +56.61% | +98.36% | 15.44B | |
| Average | +0.12% | +5.23% | +94.19% | +68.19% | 44.74B | |
| Weighted average by Cap. | +0.99% | +6.70% | +134.27% | +52.56% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.86M 66.53M 58.52M 55.17M 50.33M 94.13M 6.39B 662M 257M 3.25B 250M 244M 10.58B | 103M 72.26M 63.56M 59.92M 54.67M 102M 6.94B 719M 279M 3.53B 271M 265M 11.49B |
| Net income | 36.02M 25.26M 22.22M 20.95M 19.11M 35.74M 2.42B 251M 97.4M 1.23B 94.84M 92.78M 4.02B | 38.1M 26.72M 23.5M 22.16M 20.22M 37.81M 2.57B 266M 103M 1.31B 100M 98.15M 4.25B |
| Net Debt | -284M -199M -175M -165M -151M -282M -19.11B -1.98B -768M -9.73B -748M -731M -31.66B | -317M -223M -196M -185M -168M -315M -21.36B -2.21B -858M -10.87B -836M -817M -35.38B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-24 | US$5.780 | -0.17% | 2,354 |
| 26-09-23 | US$5.790 | -0.17% | 8,326 |
| 26-09-22 | US$5.800 | 0.00% | 4,592 |
| 26-09-21 | US$5.800 | -1.69% | 39,258 |
| 26-09-18 | US$5.900 | +0.68% | 14,557 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- CUVL Stock
Select your edition
All financial news and data tailored to specific country editions
